Subscription Drug Pricing: The Evidence Behind It Comes From Two States, And They Disagree. Zizi ElsisiandAnirban Basu September 4, 2026

https://www.healthaffairs.org/content/forefront/subscription-drug-pricing-evidence-behind-comes-two-states-and-they-disagree If CMS is to write a template for other states, or if Congress is to buy this design at national scale, it is important to understand why these policies may fail to deliver expected outcomes.